参考来源：‘Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia’，新闻稿。Solid Biosciences Inc.；2025年1月7日发布。注：本文旨在介绍医药健康研究，不作任何用药依据，具体...
参考来源:‘Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia’,新闻稿。Solid Biosciences Inc.;2025年1月7日发布。 注:本文旨在介绍医药健康研究,不作任何用药依据,具体用...
Friedreich's ataxia (FRDA) is an autosomal recessive mitochondrial disease that is characterized by neurodegeneration, diabetes and hypertrophic cardiac myopathy. The most common cause of mortality in patients with FRDA is cardiac failure, and as yet there is no treatment fo...
‘Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia’, press release. Solid Biosciences Inc.; publ...
参考来源:‘Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia’,新闻稿。Solid Biosciences Inc.;2025年1月7日发布。
‘Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia’, press release. Solid Biosciences Inc.; published on January 7, 2025. ...
参考来源:‘Solid BiosciencesAnnounces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia’,新闻稿。Solid Biosciences Inc.;2025年1月7日发布。
参考来源:‘Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia’,新闻稿。Solid Biosciences Inc.;2025年1月7日发布。
参考来源:'Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia’,新闻稿。Solid Biosciences Inc.;2025年1月7日发布。
The U.S. Food and Drug Administration (FDA) has put Lexeo Therapeutics’ LX2006, a gene therapy candidate for heart disease in people with Friedreich’s ataxia (FA), on the fast track for development. The award of fast track status aims to expedite the development and regulatory review of...